Targeting SH2 domains in breast cancer.
Houston, United States. In Future Med Chem, 2013
Herein we review phosphopeptide mimetic and small-molecule approaches targeting the SH2 domains of Grb2, Grb7 and STAT3 that inhibit their targets and reduce proliferation in in vitro breast cancer models.
The HER2 amplicon in breast cancer: Topoisomerase IIA and beyond.
Montpellier, France. In Biochim Biophys Acta, 2013
In addition it will discuss the clinical and biological implications of the amplification of ten other genes at this locus (MED1, STARD3, GRB7, THRA, RARA, IGFPB4, CCR7, KRT20, KRT19 and GAST) in breast cancer.
Targeting the calmodulin-regulated ErbB/Grb7 signaling axis in cancer therapy.
Madrid, Spain. In J Pharm Pharm Sci, 2012
In this short review we will describe the regulation exerted by the calcium-receptor protein calmodulin (CaM) on signaling routes involving the family of ErbB receptors - highlighting the epidermal growth factor receptor (EGFR/ErbB1) and ErbB2 - and the adaptor protein Grb7, a downstream signaling component of these receptors.
Relevance of breast cancer antiestrogen resistance genes in human breast cancer progression and tamoxifen resistance.
Rotterdam, Netherlands. In J Clin Oncol, 2009
PATIENTS AND METHODS: mRNA levels of 10 BCAR genes (AKT1, AKT2, BCAR1, BCAR3, EGFR, ERBB2, GRB7, SRC, TLE3, and TRERF1) were measured in estrogen receptor-positive breast tumors using quantitative reverse-transcriptase polymerase chain reaction.